PEN Stock Analysis: Buy, Sell, or Hold?
PEN - Penumbra, Inc.
$322.32
-0.65 (-0.20%)
▼
5d:
+0.03%
30d:
-2.76%
90d:
-5.0%
BUY
HIGH Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Get Alerted When PEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PEN trading at deep discount. Market pricing in -4.4% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: PEN trading at deep discount. Market pricing in -4.4% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$306.56
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$190.35
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PEN is currently trading at $322.32, which is considered oversold relative to its 30-day fair value range of $323.41 to $330.91. From a valuation perspective, the stock is trading at a discount (Forward PE: 51.2) compared to its historical average (58.6). Remarkably, the market is currently pricing in an annual earnings decline of 4.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PEN is showing sideways momentum. The price is currently testing key support at $321.38. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $363.36 (+12.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PEN is showing sideways momentum. The price is currently testing key support at $321.38. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $363.36 (+12.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$323.41 -
$330.91
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
81.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($363.36)
Trading Range Analysis
30-Day Trading Range
$323.41 -
$330.91
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$7.34
(2.3%)
Support & Resistance Levels
Support Level
$321.38
Resistance Level
$326.43
Current Trend
Sideways
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
51.19
Wall Street Target
$363.36
(+12.7%)
Revenue Growth (YoY)
15.6%
Earnings Growth (YoY)
-18.0%
Profit Margin
11.8%
Valuation Discount vs History
-4.4% cheaper
PE vs Historical
51.2 vs 58.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.4%
(market-implied from PE analysis)
1-Year Target
$308.14
(-4%)
2-Year Target
$294.58
(-9%)
3-Year Target
$281.62
(-13%)
3-Yr Target (if PE normalizes)
(PE: 51→59)
$322.40
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 51.2, Growth: 29.9%)
$706.24
(+119%)
Base:
(SPY PE: 22.1, Growth: 29.9%)
$304.51
(-6%)
Bear:
(PE: 18.8, Growth: 29.9%)
$258.83
(-20%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (75x PE), but valuation improves significantly next year (51x PE) as earnings recover.
Trailing PE: 74.62 | Current EPS (TTM): $4.33
Bull Case
$516.89
(+60%)
Analyst growth 45.4%, PE expands to 82.1
Base Case
$469.90
(+46%)
Market implied 45.4%, PE stable at 74.6
Bear Case
$219.72
(-32%)
Severe decline -20.0%, PE contracts to 63.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 51.2 to 58.6
Stabilization Target:
$369.00
(+14.5%)
PE Expansion Potential:
+14.5%
Share & Embed Analysis
Last updated: May 18, 2026 6:47 AM ET
Data refreshes hourly during market hours. Next update: 7:47 AM
Data refreshes hourly during market hours. Next update: 7:47 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Harpreet Grewal
SELL
100 shares
2026-04-02
Maggie Yuen
SELL
2432 shares
2026-03-02
Harpreet Grewal
SELL
186 shares
2026-01-06
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$85 | 59 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$83 | 66 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$389 | 58 HOLD |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$119 | 55 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$250 | 59 HOLD |
Advanced PEN Option Strategies
Professional options setups generated by AI based on today's PEN price and gamma walls.
